NCT07110038View on ClinicalTrials.gov

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

May 31, 2029

Study Completion Date

November 30, 2030

Conditions
Penile Squamous Cell Carcinoma (PSCC)
Interventions
DRUG

Avelumab

Avelumab, 1,200 mg IV

DRUG

enfortumab vedotin

Enfortumab vedotin, 1.25 mg/kg IV

Trial Locations (1)

Unknown

University Hospital Tübingen, Tübingen

Sponsors

Collaborators (1)

Astellas Pharma GmbH
All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

collaborator

Astellas Pharma GmbH

INDUSTRY

collaborator

University Hospital Tübingen

UNKNOWN

lead

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

OTHER